Abstracts Archive - Page 2259 of 2425 - ACR Meeting Abstracts

Abstract Number: 2455 • 2012 ACR/ARHP Annual Meeting
Establishment of Standardized International Units for IgG Anti-β₂glycoprotein Antibody Measurement
Rohan Willis¹, Claudia Grossi², Gabriella Lakos³, Pier Luigi Meroni⁴, Maria Borghi², Luis R. Lopez⁵, Corina Dima⁶, Marius C. Teodorescu⁷, Nicholas Ozarka⁷, Matthias Kast⁸, Nina Olschowka⁸, Alfredo Villarreal⁹, Maria Crisostomo¹⁰, Mike Watkins⁹, Wendy Vandam¹¹, Tony Prestigiacomo¹¹, Josep Puig¹², Kerrie Jaskal¹³, Roger Walker¹⁰, Sarah Paul⁹, T. Buckner¹⁴, Fernando S. Cavalcanti¹² and Silvia S. Pierangeli¹⁵, ¹Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, ³Research, INOVA Diagnostics, San Diego, CA, ⁴Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, ⁵Corgenix Inc, Broomfield, CO, ⁶Microbiology, Theratest Laboratories Inc, Lombard, IL, ⁷Microbiology, TheraTest Laboratories Inc, Lombard, IL, ⁸Phadia Thermofisher, Freiburg, MN, Germany, ⁹BioPlex Division, Bio-Rad Laboratories, Benicia, CA, ¹⁰Bio-rad Laboriatories, In, Bio-Rad Laboratories, Hercules, CA, ¹¹Bio-Rad Laboratories, Hercules, CA, ¹²Biokit, Barcelona, Spain, ¹³Instrumentation Laboratories, Bedford, MA, ¹⁴Corgenix, Broomfield, CO, ¹⁵Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Despite numerous efforts aimed at the standardization of assays for detection of anti-β2Glycoprotein I (aβ2GPI)antibodies, there are still concerns, including the type and…
Abstract Number: 2456 • 2012 ACR/ARHP Annual Meeting
Pro-Inflammatory and Pro-Thrombotic Markers in Persistently Antiphospholipid Antibody-Positive Patients with/without Systemic Lupus Erythematosus
Gurjot Basra¹, Doruk Erkan², Rohan Willis¹, JoAnn Vega³, Ana Laura Carrera Marin⁴, Patricia Ruiz Limon¹, Vijaya L. Murthy¹, Shraddha Jatwani¹, Neha Dang¹, Emilio B. Gonzalez¹ and Silvia S. Pierangeli⁴, ¹Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Research, Hospital for Special Surgery, New York, NY, ⁴Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Pro-inflammatory/thrombotic biomarkers (BMR), which are associated with aPL-mediated pathogenic effects in vitro/vivo, are also increased in aPL-positive patients. Here we examined whether those BMR…
Abstract Number: 2457 • 2012 ACR/ARHP Annual Meeting
An Open-Label Prospective Pilot Mechanistic Study of Fluvastatin in Persistently Antiphospholipid Antibody-Positive Patients
Doruk Erkan¹, Rohan Willis², JoAnn Vega³, Vijaya L. Murthy², Ana Laura Carrera Marin⁴, Gurjot Basra², Patricia Ruiz Limon², Emilio B. Gonzalez² and Silvia S. Pierangeli², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ³Research, Hospital for Special Surgery, New York, NY, ⁴Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Antiphospholipid antibodies (aPL) induce a pro-inflammatory and pro-thrombotic state by upregulating various cytokines, chemokines, and tissue factor (TF). Fluvastatin reduces TF expression and decrease…
Abstract Number: 2458 • 2012 ACR/ARHP Annual Meeting
The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infarction, and Deep Vein Thrombosis
Laura Andreoli¹, Alessandra Banzato², Cecilia B. Chighizola³, Guillermo J. Pons-Estel⁴, Guilherme Ramires de Jesus⁵, Michael D. Lockshin⁶, Doruk Erkan⁷ and On Behalf of APS Action⁸, ¹Rheumatology and Clinical Immunology, University of Brescia, Brescia, Italy, ²Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ³Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ⁴Servicio de Enfermedades Autoinmunes, Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, ⁵Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸APS ACTION, New York, NY
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international research network that has been created specifically to design and…
Abstract Number: 2459 • 2012 ACR/ARHP Annual Meeting
Efficacy of Aspirin for the Prevention of the First Thrombo-Embolic Events in Patients with Antiphospholipid Antibodies: A Metanalysis of Literature Data
Laurent Arnaud¹, Alexis Mathian², Amelia Ruffatti³, Maria Tecktonidou⁴, Ricard Cervera⁵, Ricardo Forastiero⁶, Vittorio Pengo⁷, Marc Lambert⁸, Stephane Zuily⁹, Denis Wahl⁹ and Zahir Amoura¹, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy, ⁴First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁵Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain, ⁶Favaloro University, Argentina, ⁷Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ⁸Medecine Interne Lilloise, Internal Medicine University Lille Hospital, Lille, Lille, France, ⁹Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital, Université de Lorraine & INSERM U961, Vandoeuvre-Les-Nancy, France
Background/Purpose: Whether aspirin is needed in patients with antiphospholipid antibodies (aPL+) for prevention of a first thrombotic event is controversial. The aim of this metaanalysis…
Abstract Number: 2460 • 2012 ACR/ARHP Annual Meeting
Dual Antiplatelet Therapy As Prophylaxis of Recurrent Arterial Thrombosis in Patients with　antiphospholipid Syndrome
Yuichiro Fujieda¹, Olga Amengual², Toshiyuki Watanabe¹, Michihito Kono², Yusaku Kanetsuka², Takashi Kurita², Toshio Odani¹, Kotaro Otomo¹, Toshiyuki Bohgaki², Tetsuya Horita², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Medicine II, Hokkaido University, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Arterial thrombosis (AT) is a major clinicalmanifestation of the antiphospholipid syndrome (APS). A number of studies have evaluated the rate of recurrent thromboembolism, including…
Abstract Number: 2461 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Systemic Therapies for Acute Gouty Arthritis
Kimberly Reiter¹, Jeremy Goldhaber-Fiebert² and Eswar Krishnan³, ¹Division of Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Center for Health Policy/Center for Primary Care and Outcomes Research, Stanford, Stanford, CA, ³Medicine, Standford University, Palo Alto, CA
Background/Purpose: Rising prevalence has led to increased demand for newer and potentially costly treatments for acute gouty arthritis, but few studies comparing effectiveness and costs…
Abstract Number: 2462 • 2012 ACR/ARHP Annual Meeting
Projecting the Direct Cost Burden of Osteoarthritis in Canada Using a Population-Based Microsimulation Model From [2010-2031]
Behnam Sharif¹, Jacek A. Kopec², Mushfiqur Rahman³, Nick Bansback⁴, Eric C. Sayre², Philippe Finès⁵, Hubert Wong⁶ and Aslam H. Anis⁴, ¹School of Population and Public Health, University of British Columbia, Arthritis Research Centre of Canada, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁴St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵Statistics Canada, 150 Tunney's Pasture Driveway, Ottawa, ON, Canada, Ottawa, ON, Canada, ⁶School of Population and Public Health, University of British Columbia, St Paul's Hospital, University of British Columbia, Vancouver, V6Z 1Y6, Canada, Vancouver, BC, Canada
Background/Purpose: POHEM-OA (Population Health Model-Osteoarthritis) is a population-based microsimulation model that uses Canadian Community Health Survey-2001 to generate the initial population and models every individual's…
Abstract Number: 2463 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis
Josh J. Carlson¹, Sarika Ogale², Fred Dejonckheere³ and Sean Sullivan⁴, ¹Pharmacy, University of Washington, Seattle, WA, ²Genentech, South San Francisco, CA, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: The ADACTA trial found that biologic naïve patients with severe active RA who are methotrexate (MTX) intolerant or in whom continued MTX treatment is…
Abstract Number: 2464 • 2012 ACR/ARHP Annual Meeting
Cost-Sharing and Utilization of Biologic and Non-Biologic Dmards Among U.S. Medicare Beneficiaries with Rheumatoid Arthritis
Chris Tonner, Gabriela Schmajuk and Jinoos Yazdany, Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: While Medicare's Part D prescription drug benefit expanded access to drugs for many patients, it also includes a controversial provision called the "coverage gap"…
Abstract Number: 2465 • 2012 ACR/ARHP Annual Meeting
Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season
Masatoshi Hayashi¹, Toshihisa Kojima², Naoki Ishiguro³, Tomonori Kobayakawa⁴ and Toshihisa Kanamono¹, ¹Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya Univeristy, School of Medicine, Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁴Orthopedic Surgery, Nagoya university, Nagoya, Japan
Background/Purpose: At present, annual vaccination against influenza is recommended for rheumatoid arthritis (RA) patients. However, whether humoral responses to influenza vaccine are impaired in RA…
Abstract Number: 2426 • 2012 ACR/ARHP Annual Meeting
Prevalence and Characteristics of Sleep Problems in Rheumatoid Arthritis: A Systematic Review of the Literature
Cassandra Coleman¹ and Yvonne C. Lee², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) patients commonly complain of sleep problems. Difficulties with sleep may be associated with increased fatigue, greater pain and worse quality of…
Abstract Number: 2427 • 2012 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Adolescents with Rheumatic Disease
Sandra J. Watcher¹, Maggie Sepkowitz¹, Suhas M. Radhakrishna², Anusha Ramanathan³, Liz Morasso⁴, Jennifer Chang⁵ and Jeffrey I. Gold⁶, ¹Rheumatology, Children's Hospital of LA, Los Angeles, CA, ²Pediatric Rheumatology, Kaiser Permananete Medical Group, Oakland, CA, ³Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ⁴Division of Adolescent Medicine/Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA, ⁵Anesthesiology Critical Care Medicine, Childrens Hospital Los Angeles, Los Angeles, CA, ⁶Anesthesiology & Pediatrics - Anesthesiology Critical Care Medicine, Keck School of Medicine, University of Southern California - Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Adolescents with chronic health disease face a variety of physical and psychological challenges. Adolescents with rheumatologic conditions vary with regard to their physical, emotional,…
Abstract Number: 2428 • 2012 ACR/ARHP Annual Meeting
Causal Beliefs of Disease Among Patients with Systemic Vasculitis
Peter C. Grayson¹, Naomi Amudala², Carol McAlear³, Renée Leduc⁴, Denise Shereff⁵, Rachel Richesson⁶, Liana Fraenkel⁷ and Peter A. Merkel⁸, ¹Section of Rheumatology & the Clinical Epidemiology Unit, Boston University School of Medicine, Vasculitis Center, Boston, MA, ²Rheumatology & Vasculitis, Boston University Medical Center, Boston, MA, ³Vasculitis Clinical Research Consortium, University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics Epidemiology Center, University of South Florida, Tampa, FL, ⁵Division of Bioinformatics and Biostatistics, University of South Florida, Tampa, FL, ⁶Epidemiology & Biostatistics, University of South Florida, Tampa, FL, ⁷Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Patients vary in their beliefs related to the cause of serious illness. The impact of these beliefs among patients with systemic vasculitis is not…
Abstract Number: 2429 • 2012 ACR/ARHP Annual Meeting
Balancing Work and Health: Do Younger Workers Experience More Work-Health Conflict Than Middle- and Older-Aged Workers with Rheumatic Diseases?
Arif Jetha¹, Xingshan Cao² and Monique A. Gignac³, ¹Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Divison of Health Care & Outcomes Research, Arthritis Community Research and Evaluation Unit , Toronto Western Research Institute, Toronto, ON, Canada, ³Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Research on work-life balance with healthy adults finds that difficulties balancing roles is related to negative employment outcomes. Yet, little is known about…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].